v2.4.0.6
Consolidated Statements of Income (USD $)
In Thousands, except Per Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2009
Revenues:      
Product $ 3,836,117 $ 3,470,056 $ 3,152,941
Unconsolidated joint business 996,597 1,077,244 1,094,863
Other 215,920 169,123 129,544
Total revenues 5,048,634 4,716,423 4,377,348
Cost and expenses:      
Cost of sales, excluding amortization of acquired intangible assets 466,780 400,262 382,104
Research and development 1,219,602 1,248,604 1,283,068
Selling, general and administrative 1,056,133 1,031,540 911,034
Collaboration profit sharing 317,771 258,071 215,904
Amortization of acquired intangible assets 208,566 208,928 289,811
Fair value adjustment of contingent consideration 36,065    
Restructuring charge 19,026 75,153  
Acquired in-process research and development   244,976  
Total cost and expenses 3,323,943 3,467,534 3,081,921
Income from operations 1,724,691 1,248,889 1,295,427
Other income (expense), net (13,477) (18,983) 37,252
Income before income tax expense 1,711,214 1,229,906 1,332,679
Income tax expense 444,528 331,333 355,617
Net income 1,266,686 898,573 977,062
Net income (loss) attributable to noncontrolling interests, net of tax 32,258 (106,700) 6,930
Net income attributable to Biogen Idec Inc. $ 1,234,428 $ 1,005,273 $ 970,132
Net income per share:      
Basic earnings per share attributable to Biogen Idec Inc. $ 5.09 $ 3.98 $ 3.37
Diluted earnings per share attributable to Biogen Idec Inc. $ 5.04 $ 3.94 $ 3.35
Weighted-average shares used in calculating:      
Basic earnings per share attributable to Biogen Idec Inc. 242,395 252,307 287,356
Diluted earnings per share attributable to Biogen Idec Inc. 245,033 254,867 289,476